Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

252.37
+7.833.20%
Volume:758.89K
Turnover:189.37M
Market Cap:16.38B
PE:17.25
High:252.72
Open:244.78
Low:241.39
Close:244.54
52wk High:266.38
52wk Low:123.88
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.38
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.41
PE(LYR):-43.21

Loading ...

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes Due 2032 and Concurrent Ordinary Share Repurchases

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Initial Purchasers May Buy up to $150 Mln Additional Notes

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Expects to Repurchase up to $225 Mln of Ordinary Shares Concurrently

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Net Proceeds from Offering Expected to be Used for General Corporate Purposes

THOMSON REUTERS
·
Aug 26

Piper Sandler Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 26

RBC Adjusts Price Target on Jazz Pharmaceuticals Public to $277 From $273, Maintains Outperform Rating

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Highlights Ziihera Launch, Targets $3-$5 Billion Zanidatamab Peak Sales Opportunity

Reuters
·
Aug 26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)

TIPRANKS
·
Aug 26

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Reuters
·
Aug 26

Jazz Pharmaceuticals Plc : Truist Securities Raises Target Price to $281 from $264

THOMSON REUTERS
·
Aug 26

Jazz Pharma Says FDA Approves Ziihera Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

Reuters
·
Aug 25

Jazz Pharmaceuticals - Ziihera U.S. Prescribing Information Includes Boxed Warnings for Diarrhea and Embryo-Fetal Toxicity

THOMSON REUTERS
·
Aug 25

U.S. FDA Approves Ziihera® (Zanidatamab-Hrii) with and Without Tislelizumab Plus Chemotherapy in First-Line Her2+ Advanced Gastroesophageal Adenocarcinoma

THOMSON REUTERS
·
Aug 25

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative

Simply Wall St.
·
Aug 21

Jazz Pharmaceuticals Advances Phase 3 Xywav Dosing Study in Sleep Disorders

TIPRANKS
·
Aug 20

What This Top Biotech Fund is Buying Now

Dow Jones
·
Aug 19

Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed

Simply Wall St.
·
Aug 13

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 12